afternoon, good and Iris, everyone. Thanks,
our we are forward. now The company first commercial story pivotal was quarter growth moving a for stage as Cara
to be after a available the Therapeutics your with focusing unique proposition. have that, will KORSUVA encouraging Tom recently weeks on of have detailed which planned, Injection The you programs, we of track. proceeded all first moment. few a financial I will as has value we mission, on questions. in our and progress take follow to some remain our of give launch and highlights many will US update, Cara
patients used building the treatments. Chronic currently severe, We wide pruritus is underserved leader problem pruritus. world often and is and by for it of proposition differentiated a a are intractable opportunity. this as a We in see value range in diseases,
we on path we quarter, strategic continue our three on a growth. put will Cara sustainable which priorities, to to This execute firm believe
Of course, is our KORSUVA of maximize priority the commercial first potential injection. to
launch We the are now in full U.S. mode in
As you Vifor leading US. led commercialization US efforts are our the the will pharmaceutical being recall, partner, in by renal a the company in Pharma,
will a share at we will largely more Beginning While the today early very is so more what a still picture. we of provide detailed quantitative which qualitative, will in with are paint launch, QX, stage you we data,
objectives information product and disease identification reimbursement and help patient and launch B, wholesalers; VO sales primary underway A, allow ordering; from have have dialysis product in pricing C, with awareness systems upgraded the organizations; force patient negotiations of products D, Now four the top were have contract to launch to: trajectory. to with KORSUVA pivot the weeks first enhanced our shift the to promoting E, to awareness steepen injection;
pleased expectations we am tracking to and report Now goals. of are I across our progress encouraging very to seeing these are all
Let elaborate. me
ordered nationwide. via is KORSUVA that diligently First, they The candidate product, that orders to and in pricing loaded means injection the when to can That for remember, placed. team into physician and is has clinics TDAPA ensure the a available it be a product. by to information And identified that are reimbursement reimbursement qualification. their Medicare place patient KORSUVA so can need dialysis systems a working be Vifor respective as prescribe injection is been
product have and shipped that has to received I have product clinics. Now commercial Vifor to report to product point. wholesalers pleased this dialysis to started wholesalers at ship patients am
Since pleased HCPs practice injection once KORSUVA they of to providers nurses. promoting am reached of launch the weeks. report to least aware the identification and from to injection sales the and in They KORSUVA March, promotion. Vifor that patient prescribe. and are has four force ready transitioned to starting majority And have past physicians, meetings I product are at Nephrologists Second, the in advanced
change of first-in-class product. within this poised anecdotally, product. community the pruritus. the excitement the also After KORSUVA tangible Now rides of uremic introduction to feedback new Kidney that breakthrough National the treatment nephrologists one in suggest March, evident Meeting is field interest in palpable from injection around Foundation similar this the nephrology And is wrote
Third, underway raise is new a the chronic Fund I'd awareness of drivers Significant for need. is product this through outreach to with And a been patient And education for unmet injection. a know, large-scale receive support that pruritus American population. that patients KORSUVA expanding already like the you kidney to the underserved latest be this in and pruritus is hemodialysis. long-standing campaign remind for The an awareness can Vifor, underreported key patient have work can channels. while by efforts first with you activity on patients is as demand all from payoff finally for diseases patient Kidney like treatment
U.S. patients. We total and looking baseline them. They XXX,XXX are the is confident our moderate associated product provide of can is patients that to addressable hemodialysis roughly This XX% pruritus disease. for severe answers, of kidney a with chronic market are the hemodialysis about with
Looking share progress. ahead, to second you in track the for quarter, we to metrics more expect our quantitative
of well of KORSUVA disclose the net share. Cara’s revenue as as sales will profit injection We
user This you the unit do to carry clinics inventory. is We demand end much not on shift proxy since clinics. will for update a dialysis dialysis wholesalers really good also from
the in is patients. day. first approval for followed the announced this sights. of Kapruvia next Now Europe is therapy squarely the European the in turning now our the to pruritus approved the XX, Commission, Kapruvia April markets in with U.S., opportunity in outside we was On Europe treatment available the hemodialysis U.K. by
Fresenius EU the before, balance sheet. mentioned partner, This Vifor $XX cash approval our payment we As from milestone Pharma. million triggered more adds to Care even Medical Renal payment ex strength U.S. a our
partner EU commence second We half of the Stay the tuned. in expect in of XXXX. by launch Kapruvia to the our
our advanced atopic X Now programs to second oral priority let's of oral These advancing forward are X anticipated. and Phase KORSUVA turn programs chronic moving our have pivotal non-dialysis-dependent and kidney pruritus for dermatitis. started strategic as Phase disease
Now address patients you, about moderate markets. pruritus pruritus. the suffer remind XXX,XXX have programs advanced patients In U.S., million kidney about XX severe disease. In dermatitis, from to with just atopic to significant these
we currently been insufficient. believe treatments the are these have therapies There in for right pruritus on programs capitalize these no FDA-approved either have and area we Now to opportunities. disease
clinical to priority As proof-of-concept other on an benefit the catalyst chronic second KORSUVA in is trial looking quickly. proof-of-concept approaching paresthetica the notalgia treating you Phase in track our to data paresthetica for is therapeutic third our notalgia to top in clinical expand in pruritus areas, and utility is is With of oral paresthetica. report notalgia including quarter. a recall, X efficacy establish liver next signal strategic disease. trial And line for This
indication. to inform the data path this use will in We this development
of half is primary in remains Phase our the In pruritus biliary this put, second for cholangitis addition, readout progressing on associated year. the schedule pipeline X well. Simply data
patients, of so full is we reach accelerating Cara. product approved Our the are starting to scale
over our for Tom Now, I'd details Over results. the like call to to on first you, to Tom. quarter turn
